enVVeno Medical Corporation (NASDAQ: NVNO) — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The company is a late clinical-stage medical-device developer with no current revenue, developing VenoValve, a surgical replacement venous valve, and enVVe, a transcatheter valve system.
Financial performance and liquidity
- Revenue: None. The company does not expect significant revenue until product commercialization.
- Expenses and loss: R&D expense was $3.1 million, down 14% from $3.6 million; selling, general and administrative expense was $2.5 million, down 22% from $3.2 million. Operating loss was $5.5 million versus $6.8 million, and net loss was $5.0 million versus $6.4 million, a 22% reduction.
- Other income: $0.5 million, compared with $0.4 million, including realized and unrealized gains and interest on investments.
- Per-share loss: $0.31 basic and diluted versus $0.57. The filing reports weighted-average shares of 16.057 million for Q1 2024 versus 11.231 million in Q1 2023.
- Cash flow: Operating cash use was $3.5 million, down from $5.1 million. Investing activities provided $2.2 million net, largely reflecting investment maturities net of purchases; option exercises provided $0.05 million. Cash declined $1.3 million during the quarter.
- Liquidity and obligations: Cash and short-term investments totaled $42.9 million at quarter-end, including $2.3 million cash and $40.6 million short-term investments. Working capital was $41.8 million. Total liabilities were $2.5 million, principally accounts payable and operating lease liabilities; no borrowing debt is reported. Management says resources are sufficient for obligations for at least one year after the report date, while anticipating future capital needs.
- Margins: Not meaningful because the company reported no revenue.
Changes versus Q1 2023
- Lower R&D expense primarily reflected reduced SAVVE trial outreach and enrollment costs after full enrollment in 2023; increased personnel and enVVe laboratory costs partially offset the decline.
- Lower SG&A expense mainly reflected reduced stock-based compensation. Stock-based compensation was $1.1 million versus $1.8 million.
- Net loss and operating cash use both decreased. The company attributed the lower net loss to reduced operating expenses and higher other income.
Programs, outlook, and risks
- VenoValve: The 75-patient U.S. SAVVE pivotal study completed enrollment in September 2023. Preliminary six-month results released in March 2024 showed 97% of patients had rVCSS clinical improvement and 74% achieved the stated threshold of at least three points of improvement. Preliminary follow-on data presented in April reported 94% with clinical improvement and 72% meeting that threshold at weighted-average follow-up of about 11 months. The company says the FDA requires one-year data for all 75 patients before a PMA filing; it expects to file in Q4 2024 and says it expects FDA approval eligibility in that quarter. These are company expectations, not assured outcomes.
- enVVe: Preclinical development is ongoing. The company expects to begin a six-month chronic GLP study in Q3 2024 and file for IDE approval for a pivotal study in Q2 2025. It expects enVVe to follow VenoValve by two to three years, if approved.
- Funding outlook: Management anticipates quarterly cash burn rising from approximately $4–$5 million as trials and development continue. The company says it will need to raise additional capital in the future; inability to do so could materially adversely affect it.
- Litigation: A consolidated former-employee lawsuit, which the company disputes and is defending, was set for trial on July 22, 2024. The potential loss could not be reasonably estimated and no amount was accrued at March 31, 2024.
- Other: The company reported effective disclosure controls as of March 31, 2024 and no material changes in internal control over financial reporting. It reported no off-balance-sheet arrangements.
Important facts for investors to verify
- Progress against the FDA’s requirement for one-year SAVVE data from all 75 patients, the anticipated Q4 2024 PMA filing, and eventual regulatory outcome.
- Complete and longer-term SAVVE efficacy and safety results, including follow-up on DVTs, pocket hematomas, and infections; the cited results are preliminary.
- Whether quarterly cash burn rises as forecast, the resulting cash runway, and the timing and terms of any additional financing.
- Progress and costs for enVVe’s planned GLP study and IDE filing, which remain future targets.
- The outcome and potential financial impact of the Rankin litigation, for which no loss estimate was available.
- Reconcile the reported Q1 weighted-average shares of 16.057 million with 13.330 million shares outstanding at March 31, and assess dilution: the filing lists 19.543 million potentially dilutive warrants and options excluded from diluted loss per share.